Cargando…
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
Rationale: Chemoresistance is a major obstacle in prostate cancer (PCa) treatment. We sought to understand the underlying mechanism of PCa chemoresistance and discover new treatments to overcome docetaxel resistance. Methods: We developed a novel phenotypic screening platform for the discovery of sp...
Autores principales: | Li, Xin, Gera, Lajos, Zhang, Shumin, Chen, Yanhua, Lou, Lei, Wilson, Lauren Marie, Xie, Zhong-Ru, Sautto, Giuseppe, Liu, Degang, Danaher, Alira, Mamouni, Kenza, Yang, Yang, Du, Yuhong, Fu, Haian, Kucuk, Omer, Osunkoya, Adeboye O., Zhou, Jia, Wu, Daqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171087/ https://www.ncbi.nlm.nih.gov/pubmed/34093859 http://dx.doi.org/10.7150/thno.49235 |
Ejemplares similares
-
Overcoming prostate cancer drug resistance with a novel organosilicon small molecule
por: Zhao, Rui, et al.
Publicado: (2021) -
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
por: Bai, Lijuan, et al.
Publicado: (2023) -
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative
por: Zhang, Shumin, et al.
Publicado: (2016) -
Polycomb Repressive
Complex 2 Modulation through the
Development of EZH2–EED Interaction Inhibitors and EED Binders
por: Tomassi, Stefano, et al.
Publicado: (2021) -
Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer
por: Kim, Woojin, et al.
Publicado: (2013)